3. FINANCIAL STRUCTURE Total Revenue 4.71B Total Equity 5.4 B Operating income 1.24 B Total Assets 8.1B Net income .89 B B= billion FY 2010 (consolidated)
4. CEO: George A. Scangos CFO & Management : Paul Clancy VP of R&D: Douglas Williams Regulatory: Nadine Cohen The Brains and Goals Behind Biogen Idec Business Goals as of 2007: -- 100,000 patients on TYSABRI(R) (natalizumab); Not yet met. -- More than 40% of the Company's revenue coming from its International business; Not yet met. -- Four new products and/or existing products launched in new indications; Not yet met. -- Six programs in late-stage clinical development. Goal achieved.
